Ascendis Pharma A/S (ASND) intrinsic value & 10-year financials
Ascendis Pharma A/S (ASND) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 75.3% a year to $720.1M, with an average return on invested capital of -76.5%.
- Graham intrinsic value
- —
- Revenue (FY2025)
- $720.1M
- Revenue growth (10-yr CAGR)
- 75.3%
- ROIC (10-yr avg)
- -76.5%
- Free cash flow (FY2025)
- —
ASND 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $720.1M | -$228.0M | — | — | — | 169.8% |
| FY2024 | $363.6M | -$378.1M | — | — | — | 300.8% |
| FY2023 | $266.7M | -$481.4M | — | -$469.8M | — | -818.4% |
| FY2022 | $51.2M | -$583.2M | — | -$510.2M | — | -101.7% |
| FY2021 | $7.8M | -$383.6M | — | -$441.4M | — | -44.5% |
| FY2020 | $7.0M | -$419.0M | — | -$291.4M | — | -58.4% |
| FY2019 | $13.4M | -$218.0M | — | -$181.1M | — | -49.7% |
| FY2018 | $10.6M | -$130.1M | — | -$141.4M | — | -55.7% |
| FY2017 | $1.5M | -$123.9M | — | -$96.0M | — | -68.1% |
| FY2016 | $4.6M | -$68.5M | — | -$60.9M | — | -38.8% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Ascendis Pharma A/S is a consistent compounder, expanding top-line revenue at 75.3% annually over the past decade.
Ascendis Pharma A/S has historically struggled to out-earn its cost of capital, averaging just -42.0% ROIC.
Ascendis Pharma A/S capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Ascendis Pharma A/S is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment.